Value-Based Pricing for Emerging Gene Therapies: The Economic Case for a Higher Cost-Effectiveness Threshold

Vol. 25, No. 7, July 2019 JMCP
Journal of Managed Care & Specialty Pharmacy

 

Overview

 

Sentero Pharma partner, Mike Kenston, co-authored a recent article discussing various approaches for valuing one-time gene replacement therapies, including methods such as:

  • Health technology assessments

  • Value of a statistical life

  • Welfare economics theory

  • Analogue analysis

Application

 

For any company assessing the commercial potential of a gene therapy, it is critical to thoroughly construct relevant value frameworks and evaluate the receptivity of stakeholders who will ultimately determine patient access to the therapy.

We can assist you in developing the appropriate value frameworks and assessing how these approaches can impact your success.

You will gain significant insights into how to communicate the value of the new therapy as well as understand the impact on commercial potential.